18 November 2022
Latham Represents CytomX in Collaboration and Licensing Agreement With Regeneron Pharmaceuticals
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Judith Hasko Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Mike Sweeney | Latham & Watkins LLP | Associate | corporate | Los Angeles |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | Bay Area |
| Alex Farris | Latham & Watkins LLP | Associate | tax | Not stated |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- CytomX Therapeutics, Inc.Joint venture party
- Counterparties
- Regeneron Pharmaceuticals, Inc. (Joint venture party)